Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
|12/07/2019||Appendix 3Y-Dr William Garner||Download|
|12/07/2019||Change in substantial holding||Download|
|12/07/2019||Ceasing to be a substantial holder||Download|
|05/07/2019||Appendix 3Y-Dr William Garner||Download|
|28/06/2019||Appendix 3Y-Dr William Garner||Download|
|28/06/2019||Change in substantial holding||Download|
|14/05/2019||Bisantrene AML trial to start in Israel||Download|